DNMT3A R882 mutations in AML promote chemoresistance and therapeutic relapse - European Medical Journal
×

Browse

DNMT3A R882 mutations in AML promote chemoresistance and therapeutic relapse

|
Oncology

Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882 mutations were associated with an increased risk of minimal residue disease (MRD) at the time of complete remission. DNMT3A R882 mutations may therefore be important in chemoresistance in AML. A novel genetic mouse model was used to study the role of DNMT3A R882 mutations in AML pathogenesis and chemoresistance.

Presented by Olga Guryanova, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, at the 20th Congress of the European Hematology Association (EHA).